Oribiotech Ltd Secures £10.8k in Latest Funding Round

London-based biotechnology manufacturing specialist Oribiotech Ltd has finalized a £10.8k pre-seed funding round, reaching an estimated post-money valuation of £17.2m. The transaction was officially filed on March 12, 2026, following an initial share allotment on September 22, 2025.

Incorporated in September 2015 by founders Chris Mason and Farlan Veraitch, Oribiotech develops the IRO platform, an automated manufacturing technology built to digitize and standardize the production of cell and gene therapies. The production of these advanced therapies has traditionally been highly manual, expensive, and difficult to scale. Oribiotech solves this problem by providing a closed, automated system that integrates bioreactor hardware, single-use consumables, and software to control and track cell processing. This approach increases throughput, improves reproducibility, and reduces the overall cost of goods. The company supplies these scalable manufacturing solutions to a specialized client base, including therapy developers, contract development and manufacturing organizations, and academic researchers.

Operating under the leadership of Chief Executive Officer Jason C. Foster, the company has established a solid operational footprint. By the end of 2024, Oribiotech reported revenues of approximately £474k and employed a team of 52 people.

The current £10.8k pre-seed classification represents a highly unusual administrative filing for a company of this maturity. Oribiotech is already a heavily venture-backed entity, having previously secured a £23m Series A round in 2020 and a £75.9m Series B round in January 2022. Those earlier rounds attracted major institutional capital from investors including Novalis LifeSciences, Amadeus Capital Partners, Northpond Ventures, and Octopus Ventures. While the latest £10.8k allotment is fractional compared to its historic capital raises, it officially values the enterprise at £17.2m post-money. Specific investors for this minor top-up were not disclosed in the filing.

Oribiotech's technology addresses a critical bottleneck within the broader UK life sciences ecosystem. The United Kingdom remains the dominant force in European biotechnology venture capital. According to recent data from the BioIndustry Association, UK biotech companies raised £1.9 billion in equity financing throughout 2025. Despite a highly selective investment climate, the sector saw a strong finish to the year with 22 completed deals in the fourth quarter, demonstrating resilient investor appetite for UK science.

The advanced therapy sector in the UK is particularly active, currently hosting over 90 advanced therapy companies. In 2025, the UK recorded 193 ongoing clinical trials for advanced therapy medicinal products, with 56 percent of these being early-stage studies. This indicates a robust pipeline of future therapies that will eventually require commercial-scale manufacturing. As these treatments progress from the laboratory to the clinic, the industry faces severe manufacturing constraints. Investors and health systems are increasingly focused on scalable, cost-effective production models rather than just clinical efficacy. By automating the complex biological manufacturing process, Oribiotech provides the